Featured News
Your Guide to IND-Enabling Study Needs
What Sponsors Should Know Before IND Submission
An Investigational New Drug (IND) application is the regulatory gateway allowing sponsors to begin human clinical trials in the United States. According to the U.S. Food and Drug Administration, an IND must include nonclinical pharmacology and toxicology data demonstrating that a drug is reasonably safe for initial human testing.
IND-enabling studies generate the scientific evidence needed to support this submission. These programs sit at the intersection of discovery, safety assessment, manufacturing, and regulatory strategy. They are most effective when built within an integrated preclinical development framework.
What are IND-enabling studies?
IND-enabling studies are nonclinical experiments and analyses that establish biological activity, characterize exposure, and define safety margins before first-in-human trials. They are typically conducted as part of coordinated safety assessment programs and regulatory submission planning.
Core Components of an IND Program
- Pharmacology and Target Engagement
Pharmacology studies confirm that a drug reaches and modulates its intended biological target, building on evidence established during hit identification and screening, hit-to-lead development, and lead optimization studies. - ADME, DMPK, and Bioanalysis
ADME and DMPK studies characterize absorption, distribution, metabolism, and excretion, while drug-drug interaction studies and validated bioanalytical methods support dose selection and safety interpretation. - Toxicology and Safety Pharmacology
General toxicology studies, genetic toxicology testing, and safety pharmacology assessments identify target organ risk and establish margins of safety. - CMC and Clinical Alignment
Chemistry, manufacturing, and controls development, formulation support, and stability programs ensure product quality and clinical relevance. - Regulatory Data and SEND Compliance
Nonclinical data must comply with SEND requirements and regulatory data management standards to support an efficient FDA review.
Common IND-Enabling Challenges
Many programs face delays due to fragmented study sequencing, late safety findings, incomplete exposure data, or misaligned clinical planning. Integrated program management and scientific advisory services help mitigate these risks.
IND-Enabling Timeline
Most IND programs require 18-36 months from candidate selection to submission, depending on modality and indication. Early use of IND readiness roadmaps and digital planning platforms supports proactive timeline management.
Webinar: Changing Tides, Headwinds, and Opportunities in Drug Development of the Future
Explore the future of preclinical drug development in this webinar, where you'll learn to adapt strategies for a changing regulatory landscape, streamline processes, and leverage innovative technologies like AI/ML for a competitive edge.
Watch on demand
How much does it cost to file an IND?
There is no application fee when submitting an IND application. The primary investment lies in the IND-enabling program, which generates the nonclinical, CMC, and safety data required to support first-in-human studies and regulatory confidence.
For most programs, small-molecule, IND-enabling packages typically range from $2-7 million, while biologics and advanced modalities often exceed this range due to increased complexity in study design, bioanalysis, manufacturing, and toxicology requirements.
Actual costs vary based on modality, therapeutic area, regulatory expectations, and overall development strategy. Early scientific and regulatory alignment is critical to designing fit-for-purpose programs that manage risk, control costs, and support timely IND submission.
Our Scientific Advisory Services can help sponsors define the right IND-enabling strategy early, aligning study design and regulatory expectations to optimize timelines, cost, and development success.
Building IND Readiness with Confidence
An integrated, multidisciplinary approach reduces regulatory risk, improves data quality, and accelerates clinical entry. Sponsors who combine scientific rigor with regulatory insight and program-level oversight are best positioned to advance from discovery to first-in-human trials.
Learn how our IND support services joined forces with Invizius to launch their first-in-human trial for a revolutionary hemodialysis solution.
If you’re ready to start your IND application, request a consultation with our experts first to ensure you have the necessary elements for a seamless submission.